Prelude Corporation (PreludeDx(tm)), a leader in precision diagnostics for breast cancer, today highlighted a new milestone for DCISionRT(r), its validated genomic test that provides individualized recurrence risk assessment and predicts radiation therapy benefit for women diagnosed with ductal carcinoma in situ (DCIS).